A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line

NADIA BENABBOU1, PEZHMAN MIRSHAHI1, CAMILLE BORDU1, ANNE-MARIE FAUSSAT2, RUOPING TANG3, AMU THERWATH1, JEANNETTE SORIA1, JEAN-PIERRE MARIE2 and MASSOUD MIRSHAHI1

1UMR, Paris Diderot, Paris 7 University, Lariboisière Hospital, INSERM U965; 2Department of Hematology, 3Tumor Bank ‘Leukemia’, Saint-Antoine Hospital, Paris, France

Received April 15, 2014; Accepted June 5, 2014

DOI: 10.3892/ijo.2014.2569

Abstract. The importance of the insulin-like growth factor, IGF, as a signaling axis in cancer development, progression and metastasis is highlighted by its effects on cancer cells, notably proliferation and acquired resistance. The role of the microenvironment within which cancer cells evolve and which mediates this effect is far from clear. Here, the involvement of IGF-I in inducing multidrug resistance in a myeloid leukemia cell line, grown in the presence of bone marrow-derived stromal cells called ‘Hospicells’ (BMH), is demonstrated. We found that i) drug sensitive as well as resistant leukemia cells express IGF-I and its receptor IGF-IR. However, the resistant cells were found to secrete high levels of IGF-I. ii) Presence of exogenous IGF-I promoted cell proliferation, which decreased when an inhibitor of IGF-IR (picropodophyllin, PPP) was added. iii) BMH and IGF-I are both involved in the regulation of genes of the ATP binding cassette (ABC) related to resistance development (MDR1, MRP1, MRP2, MRP3 and BCRP). iv) The levels of ABC gene expression by leukemia cells were found to increase in the presence of increasing numbers of BMH. However, these levels decreased when IGF-IR was inhibited by addition of PPP. v) Co-culture of the drug-sensitive leukemia cells with BMH induced protection against the action of daunorubicin. This chemoresistance was amplified by the presence of IGF-I whereas it decreased when IGF-IR was inhibited. Our results underline the role of microenvironment in concert with the IGF-1 pathway in conferring drug resistance to leukemia cells.

Introduction

A major problem in the treatment of leukemia is the appearance of multi-drug resistance (1). Chemoresistance often is at the origin of a major number of relapses which are mediated by the expulsion activity of the ABC pumps. The microenvironment is intimately related to the development of drug resistance in cancer cells. However, the precise nature of molecular events in action between the stromal and leukemic cells remains still elusive. Chemoresistance of leukemic cells, besides the microenvironment is also controlled by the ATP binding cassette genes (ABC), notably ABCB1 (MDR1) which code for the P-gp protein. In a rather unorthodox series of experiments we identified recently the presence of a distinct population of stromal cells in the tumor microenvironment which we baptized ‘Hospicells’ (BMH). These cells were found to establish very particular relationship with HL60 (acute leukemia cell lines), MDA-MB-231-GFP (breast cancer cell line) and OVCAR-3GFP (ovarian cancer cell line) (2-7). In solid tumors, the very presence of Hospicells were found to confer drug resistance to cancer cells during chemotherapy via oncologic trogocytosis (2,3), as a result of upregulation of ATP binding cassette gene family (4). Hospicells by their presence promotes tumorigenicity and angiogenesis (5) besides influencing the immune response of tumor microenvironments (6,7). A plethora of cell metabolic functions such as vasculogenic mimicry, cancer cell proliferation, inhibition of cell death and metastasis are known today to be influenced by IGF-1 (8-20).

This is the first report concerning the effect of IGF-I on the regulation of the ABC genes (MDR1, MRP1, MRP2, MRP3, MRP5 and BCRP) in leukemic cells when they are put in contact with a subset of bone marrow derived stromal cell named Hospicells.

Materials and methods

Cell culture. Four cell lines were used in this study, HL-60, (acute promyelocytic leukemia ATCC, CCL-240), K-562 (chronic myelogenous leukemia ATCC, CCL 243), K562 (acute promyelocytic leukemia ATCC, CCL-240), K-562.
and HL60 derived from K562/Dox and HL60/Dnr, which were developed as daunorubicin and doxorubicin resistant lines, respectively. These cells are deposited at the Leukemia Tumor Bank, Hôpital Saint Antoine, Paris. The phenotype for HL60 wild-type (CD13+, CD15+, CD33+ CD34+, CD19+, HLA-Dr) and for K562 wild-type (BCRAbl+ ‘Philadelphia chromosome’, CD13+, glycoporphin+ and CD3+, CD19+) were determined by flow cytometry. These two cell lines are routinely used as reference cells for chromosome analysis.

RPMI-1640 containing 10% fetal bovine serum (FBS), 1% and 15% FBS. The bone marrow Hospicells were isolated as described (21). The contaminating monocytes in the mononuclear cell population were excluded by adhesion on plastic plates for 30 min. Then, the non-adherent cells were collected and cultured for 2 weeks in wells coated with 0.2% gelatin in endothelial cell basal medium MV2 (Promocell, Heidelberg, Germany) supplemented with final concentrations of 1 g/ml ascorbic acid, 10 ng/ml b-FGF, 5 ng/ml EGF, 20 ng/ml insulin growth factor-1 (IGF-1), 0.5 ng/ml VEGF and incubated at 37°C in 5% CO₂ atmosphere.

**Bone marrow Hospicells.** Hospicells were isolated from eight AML bone marrows (Hôpital Hotel Dieu, Paris). The bone marrow-adherent mononuclear cell population (BMMNCs) isolation was carried out by Ficoll density gradient centrifugation as described (21). The contaminating monocytes in the mononuclear cell population were excluded by adhesion on plastic plates for 30 min. Then, the non-adherent cells were collected and cultured for 2 weeks in wells coated with 0.2% gelatin in endothelial cell basal medium MV2 (Promocell, Heidelberg, Germany) supplemented with final concentrations of 1 g/ml ascorbic acid, 10 ng/ml b-FGF, 5 ng/ml EGF, 20 ng/ml insulin growth factor-1 (IGF-1), 0.5 ng/ml VEGF and 15% FBS. The bone marrow Hospicells were isolated as described (2-7).

**Adhesion assay.** Adherent BMMNCs (10⁵) were seeded in 6-well plates with their respective culture medium and left to adhere. After completion of cell adhesion, they were washed twice with PBS. HL60 (3x10⁵) were plated onto the adherent cell monolayer at 37°C for 24 min. Then, the supernatant containing non-adherent cells was discarded and the cell monolayer was again washed twice with PBS. The number of BMH in the adherent cell population, obtained after 24 h culture was evaluated. When 5 or more leukemic cells adhered to a single bone marrow stromal cell the latter was considered to be a Hospicell.

**Treatment of cells with IGF-I and IGF-IR inhibitor.** The leukemic cell lines were incubated with IGF-I (200 ng/ml) and IGF-IR inhibitor PPP (picropodophyllin, 1 µM) from Calbiochem (Paris).

**Reverse transcription and polymerase chain reaction (RT-PCR).** Total RNA was extracted with the Nucleospin RNA II kit (Macherey-Nagel EURL, Hoerde, France). Reverse transcription was performed using M-MLV reverse transcriptase and oligo(dt) primers (Gibco-BRL, Paisley, UK). The polymerase chain reaction (PCR) was performed by Taq DNA polymerase (Gibco-BRL). Specific primers for IGF-I (sense: 5′-AAA TCA GCA GAT TGG TCT CAA C-3′ and antisense: 5′-CTT CTG GGT GCT TTT GGG CAT GT-3′); IGF-II (sense: 5′-AGT CGA TGC TGG CTT CTC A-3′ and antisense: 5′-GGG GGC GGT GTT TGG GTG GGT AG-3′); IGF-IR (sense: 5′-GAC ATC CGC AAC GAC TAT CAG A-3′ and antisense: 5′-GTA GTT ATT GGA CAC CGC ATC-3′); IGF-IR (sense: 5′-TAC AAC TTC CGG TGG TAC ACC A-3′ and antisense: 5′-CAT GGC ATACCA GGT TCT TCC A-3′); MDR1 (sense: 5′-GTT ATG AGA AGT TTG TTG-3′ and antisense: 5′-AAA AAC TAT CCC ATA ATA AC-3′); MRP (sense: 5′-AAT GCG CCA AGA CTA GGA AG-3′ and antisense: 5′-AGG GGA GGA TGT TGA ACA AG-3′); MRP2 (sense: 5′-CGT GAT GAA GCC TCT GA-3′ and antisense: 5′-CTG CCA TAA TGT CCT GGT TC-3′); MRP3 (sense: 5′-GCA GGT GAT ATT TGC TCT GA-3′ and antisense: 5′-CCT CTC TAT GAC CAG TAC AG-3′); BCRP (sense: 5′-GGA TAA TCT CTT CTC AGT GGG-3′ and antisense: 5′-GGA ATG GCA ATG CTC TAA AG-3′); 

**IGF expression by leukemic cells.** The presence of proteins belonging to IGF family in cell lines was revealed by immunocytochemistry. Cells were seeded and fixed at 20,000 cells/well in glass bottom chamber slides (Nunc, Lab-Tek, Naperville, IL, USA). They were then permeabilized and incubated for 2 h at room temperature either with specific primary antibodies (dilution 1/200) anti-IGF-I, -II, -IIR or -IIR (R&D Systems, Minneapolis, MN, USA). After several washes, the cells were incubated successively with biotinylated secondary antibody and streptavidine coupled to fluorescein isothiocyanate (dilution 1/500), for 45 min. Isotypic controls were performed concurrently and nuclei were DAPI-labeled. The cells were then visualized by fluorescence microscopy.

**Analysis of P-gp expression.** P-gp was studied by using UIC2 (Immunotech, France), monoclonal antibody, followed by labeling with a secondary antibody conjugated with phycoerythrin. Cells (1x10⁶) were fixed and permeabilized using IntraPrep™ (Beckman Coulter, Villepinte, France) as per the manufacturer's instructions. Fluorescence was measured and analyzed by flow cytometry. Protein expression for each transporter was quantified as the mean fluorescence intensity (MFI) shift (ratio of the MFI of antibody and isotype control). All experiments were performed in triplicate.

**Studies of drug resistance of HL60 and HL60/Dnr cells in the presence of Hospicells.** The Hospicells were seeded first to 60% confluency in a 96-well flat-bottomed culture plate with complete medium containing 10% FBS. After 18 h incubation, the leukemic cells (10,000 cells/well) were added and co-cultured for 24 h with Hospicells in the presence of IGF-I (200 µg/ml) or IGF-IR inhibitor (1 µM before addition of daunorubicin). The effect of these cytotoxic agents was evaluated by optical density (OD) measurement using the multi-well plate reader (Wallac, Perkin-Elmer, Waltham, MA, USA). The result is representative of three independent experiments.

**Statistical analyses.** The results are presented as mean ± SE and data were analyzed using Student's t-test P-value (<0.05 was considered significant).
Results

Expression of IGFs and IGF-R by leukemic cells. Fig. 1A shows the four cell lines (HL60 and K562 sensitive and resistant) the difference in transcription levels of IGFs and their receptor genes. These results were confirmed at the protein level by immunocytochemistry (Fig. 1B and C). Fig. 1D indicates the amount of IGF-I in the supernatants of the sensitive and resistant cells. The results show that the resistant cells secrete more IGF-I (50 pg/ml) than the sensitive cells (<5 pg/ml).

Expression of P-gp by the sensitive and resistant cells. The MDR1 gene coding P-gp protein was studied by the RT-PCR. Fig. 2A shows that MDR1 mRNA is strongly expressed by resistant cells whereas the sensitive cells not at all. These results were confirmed by flow cytometry of P-gp protein (Fig. 2B). The ratios of the Mean Fluorescence Intensity (MFI) of P-gp in resistant cells as against the value for controls are presented in Fig. 2C. Thus it can be inferred that the drug expulsion mechanism is active in the resistance cells and not in the controls.

The effect of IGF-I on cell proliferation. The effect of IGF-I on the proliferation rate of sensitive K562 and HL60 and resistant K562/Dox and HL60/Dnr cells are shown (Fig. 3A and B). The rate of proliferation of the sensitive cells was lower than that of the resistant ones. These results show that IGF-I promotes proliferation, its effect being more important in the resistant cells than in the sensitive cells.

We also determined the effect of the cycloclinan PPP, an IGF-IR inhibitor (22), on the resistant cells which express P-gp: HL60/Dnr (Fig. 3C) and K562/Dox (Fig. 3D) and sensitive cells K562 and HL60 which do not. The values of the IC<sub>50</sub> of PPP in these cells were evaluated by MTT tests. Fig. 3E (see table inserted) shows that the value of the IC<sub>50</sub> of PPP is higher in the resistant cells as compared to sensitive cells.

IGF-I mediated expression of MDR1 mRNA and P-gp in the sensitive and resistant cells. Fig. 4A shows induction of MDR1 mRNA expression and its protein P-gp (Fig. 4B) in cells treated by IGF-1. This expression of P-gp, induced by IGF-I, is inhibited by the presence of PPP in both resistant and sensitive cells. The results suggest that IGF-I, via IGF-IR, is able to induce and control the expression of P-gp, the major protein implicated in chemoresistance.

Regulation of ABC genes by IGF-I. Normally, the expression of MRP1, MRP2, MRP3 and BCRP is low or non-existent in the 4 cell lines (K562, K562/Dox, HL60 and HL60/Dnr), whereas MRP5 is strongly expressed (Fig. 5). In the K562 and
its derivative K562/Dox cells, the expression of MRP3 and BCRP increased significantly in the presence of IGF-I. On the other hand, the expression of MRP3 and BCRP, in these same cells decreases or disappears in the presence of PPP.

In HL60/Dnr, we found no significant difference in the expression of MRP1 mRNA in the presence of IGF-I, however, exposure to PPP in the medium led to the inhibition of MRP1 gene expression. We found no difference in the expression of BCRP and MRP2 mRNAs in the HL60 cells and its derivative HL60/Dnr. Whereas, the expression of MRP5 gene was not affected by addition of IGF-I nor that of PPP.

**Expression of IGF, IGF-R and MDR1 by Hospicells.** Hospicells from the stroma were identified because of their property to interact with HL60 cells. Fig. 6A shows HL60 interaction with a subset of stromal cells (Hospicells) and Fig. 6B with the enriched population of Hospicells. These cells express IGF-I, IGF-II, IGF-1R and IGF-IIR, as studied by immunocytochemistry (Fig. 6C) and P-gp (MDR-1) mRNA by RT-PCR (Fig. 6D).

**Transcriptional regulation of the ABC genes through the association of HL60 with Hospicells.** The number of Hospicells was counted in each bone marrow stroma preparation. It varied from 3 to 9.7% of the total stromal cells. In normal bone marrow only 0.7% of stromal cells are Hospicells (data not shown). Three samples were chosen from AML bone marrow depending on the number of Hospicells (Fig. 7A). Fig. 7B shows that HL60 cells express mRNA for MDR1, MRP2 and MRP3 in the presence of the Hospicells whereas it was not expressed in control cells. Moreover, the level of expression of ABC genes was directly related to the number of Hospicells present initially in the three BM samples. However, no difference in the expression of MRP5 in the presence of the Hospicells compared to the control was seen (Fig. 7C).

Fig. 7D and E show that HL60 cells co-cultivated with Hospicells from AML (N3 rich in Hospicells), express the ABC genes. On the other hand, the addition of PPP decreased the expression of MDR1 and MRP1 as also the BCRP.

These results are interesting since it may suggest that IGF-I was secreted by Hospicells or HL60 cells and acts through autocrine and/or paracrine mechanisms on MDR1, MRP1, MRP2 and BCRP genes.

**Interaction between HL60 and Hospicells in the presence of IGF-I and induction of chemoresistance.** Our results show that under culture conditions (without treatment), HL60 sensitive cell proliferation is stimulated by IGF-I (P=0.02) whereas this strongly diminishes in the presence of PPP (P=0.002). This indeed confirms our earlier results (Fig. 8A). In the presence of Hospicells, we observed a significant increased proliferative activity of HL60 cells (P=0.03) as compared to controls. HL60 cells when in physical contact with the Hospicells display a clear resistance to daunorubicin. This resistance is reinforced further by IGF-I (P=0.03) whereas it decreases in the presence of PPP (P=0.02).

These observations confirm that, on one hand IGF-I regulates ABC gene expression (mainly MDR1), whereas Hospicells provide protection to HL60 leukemic cells against the effect of chemotherapy. Fig. 8B depicts the interaction between

---

**Figure 2.** Expression of P-gp by the leukemic cells. MDR1 mRNA expression was studied in K562, K562/Dox, HL60 and HL60/Dnr cells by RT-PCR using β2-microglobulin as control (A). Flow cytometry analysis of P-gp in these cells using anti-CD243-phycocerythrin (B). P-gp expression was quantified as the mean fluorescence intensity (MFI) shift (ratio of the MFI of P-gp and isotype control) (C).
HL60/Dnr cells and Hospicells in the presence of IGF-I and the enhancement of chemoresistance. It shows that proliferation of these resistant cells is stimulated by IGF-I (P=0.0002), whereas it decreases in the presence of PPP (P=0.0003). Thus the interaction between Hospicells and HL60/Dnr cells increases the proliferation of the resistance cells which is further amplified
Figure 5. Regulation of the ABC genes by IGF-I. The four leukemic cell lines were incubated in the presence of IGF-I (200 ng/ml) or PPP (0.5 µM for the HL60 and K562; 1 µM for K562/Dox and HL60/Dnr) for 12 h at 37°C. Then, a RT-PCR was carried out to study the expression of mRNAs for MRP1, MRP2, MRP3, MRP5 and BCRP with β2-microglobulin as a control.

Figure 6. Expression of IGFs, IGF-R and MDR1 in Hospicells from AML bone marrow. Hospicells were identified among other stromal cells because of their property to interact with HL60 cells (A). Interaction of HL60 with enriched Hospicells (B). The Hospicells were stained by IGF-I, -II, -IR and -IIR antibodies (C). Expression of MDR1 by Hospicells was analyzed by RT-PCR (D).
by the presence of IGF-I. The inhibition of IGF-IR by the addition of PPP reduces this drug resistance.

**Discussion**

Of the two insulin-like growth factors, IGF-I and IGF-II, IGF-I binds to two distinct cell surface receptors named IGF receptor-I (IGF-IR) and the insulin receptor (INSR). The binding of IGF-I/IGF-IR occurs at a higher affinity than IGFI/INSR binding. IGF-IR is a transmembrane tyrosine kinase receptor and is activated by IGF-I and IGF-II (24-27). IGF-II binds to the IGF-II receptor and acts as a signaling antagonist. IGF-I and IGF-II form complexes with insulin-like growth factor binding protein (IGFBP). Integrin αvβ3 also plays an important role in IGF-IR signaling and its biological functions (28). Several studies have shown that

---

Figure 7. Expression of the ABC genes by HL60 cells co-cultivated with Hospicells. The Hospicells from three bone marrows of AML were counted and expressed as a percentage compared to the total number of mesenchymal stromal cells (A). HL60 cells co-cultivated with the Hospicells of three bone marrows for 12 h and the expression of ABC genes were analyzed by RT-PCR (B). The ratio of ABC gene expression/β2-microglobulin is presented in (C). HL60 cells co-cultivated with Hospicells from AML (N3) bone marrow for 12 h in presence or not of PPP, an RT-PCR was carried out to study the ABC gene expression: MDR1, MRP1, MRP2, MRP3, MRP5 and BCRP (D). The ratio of ABC gene expression/β2-microglobulin is presented in (E).
IGF-I is involved in the progression of malignant hematologic diseases (23).

During this study, the characteristics of the myeloid cell lines, both sensitive and resistant to the agents of chemotherapy, were defined by studying the expression of MDR1 and its protein P-gp. In addition, the proliferative effect of IGF-I on sensitive or resistant cells and the effect of the IGF-IR inhibitor (PPP) were ascertained. It was noted that the basal level of proliferation of the resistant cells was well above that of the sensitive cells. Exogenous addition of IGF-I stimulated proliferation of the two cell lines without marked difference.

The degree of resistance displayed by HL60 (in contact with Hospicells) was more pronounced when the proportion of Hospicells in givens stroma was high. This was partially abolished by the addition of PPP. However, MRP5 was an exception and remained unchanged. The addition of IGF-I increased the expression of P-gp which could be inhibited again by PPP. The co-cultures of Hospicells with sensitive leukemic cells showed that the Hospicells were able to transmit the character of drug resistance to the sensitive cells. We had previously provided evidence that bone marrow stromal cells secrete significant amounts of FGF (fibroblast growth factor), SDF-1α (stromal cell-derived factor 1) and IGF-1 (8). In the present study we report that bone marrow Hospicells also secrete IGF-1. Consequently, IGF (via autocrine or paracrine pathway) could be considered a strong candidate for the regulation of ABC genes and chemoresistance of HL60 cells.

In an unpublished study we had observed that the interaction of cancer cells with BMH was integrin-dependent. Cell-cell interaction activates integrin signaling pathway which play a crucial role in IGF signaling (28). The IGF-IR and its ligands may also promote growth of metastatic cells in the bone, the preferred site of metastases (29). Recently, we reported that Hospicells from solid tumors can be involved in chemoresistance via oncologic trogocytosis, i.e., through transfer of MDR proteins onto the incoming cancer cells (2) or upregulation of the ABC genes (3). The IGFs are among the more abundant growth factors in bone tissue and are synthesized by various bone marrow cells including stromal cells (8) and BMH. Within the microenvironment, the stromal Hospicells, in concert with IGF-1, provide strong synergetic effect for the maintenance and proliferation of cancer cells. In addition, BMH may represent a niche for homing of cancer cells and the secretion of IGF-1 which provide protection while promoting their proliferation and chemoresistance.

Our results demonstrate that tumor stromal cells contribute in the physiopathological response to IGF-1/IGF-IR. Targeting IGF-IR in multiple myeloma (30) and breast cancer (31) indicated a decrease in the formation of tumors and a diminuation of angiogenesis. In view of the scant attention given so far to the role of microenvironment, in the behavior and biology of the leukemic cells, we have focused attention in the present study on the intimate relationships between Hospicells, IGF-1 and malignant cells.

IGF and IGF1R expression levels are relevant indicators of tumor stage and/or disease progression. Additional studies will be necessary to further clarify the mode of action of the ABC pumps as also other pumps such as LRP (lung resistance-related protein). Curiously IGF seems not to have any effect on MRP5 gene expression.

In conclusion our results suggest the importance of the microenvironment and the IGF-I pathway in drug resistance of leukemic cells. A better knowledge of this close relationship can be helpful in the search for new openings in cancer therapy.

References

1. Baudard M, Beauchamp-Nicoud A, Delmer A, Rio B, Blanc C, Zittoun R and Marie JP: Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 13: 1481-1489, 1999.
2. Rafii A, Mirshahi P, Poupot M, Faussat AM, Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J, Bergalet J, Querleu D, Dagonnet F, Fournié JJ, Marie JP, Pujo-le-Lauraine E, Favre G, Soraj J and Mirshahi M: Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PlOoS One 3: e3894, 2008.
3. Lis R, Capdet J, Marshia P, Lacroix-Triki M, Dagonnet F, Klein C, Mirshia M, Fournie JJ, Raffi A and Poupot M: Oncologic trogocytosis with Hospicells induces the expression of N-cadherin by breast cancer cells. Int J Oncol 37: 1453-1461, 2010.

4. Benabbou N, Mirshia P, Cadillon M, Soria J, Therwath A and Mirshia M: Hospicells promote upregulation of the ATP binding cassette genes by insulin like growth factor-I via JAK2-STAT3 signaling pathway in ovarian cancer cell line. Int J Oncol 43(5): 685-694, 2013.

5. Pasquet M, Golzio M, Mery E, Raffi A, Benabbou N, Mirshia P, Hennellebe I, Bourin P, Allal B, Teissie J, Mirshia M and Couderc B: Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 126(2): 2090-2101, 2010.

6. Martinet L, Poupot R, Mirshia P, Raffi A, Fournie JJ, Mirshia M and Poupot M: Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer 126(2): 2143-2152, 2010.

7. Castells M, Thibault B, Mery E, Golzio M, Pasquet M, Hennellebe I, Bourin P, Mirshia M, Delord JP, Querleu D and Couderc B: Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages. Cancer Lett 326: 59-68, 2012.

8. Marzac C, Calandini OA, Marie JP, Soria C, Soria J and Mirshia M: Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia 23: 1039-1048, 2009.

9. Wu X, Tortolero-Luna G, Zhao H, Phtak D, Spitz MR and Follen M: Serum levels of insulin-like growth factor-I receptor and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res 9: 3356-3361, 2003.

10. Yang SY and Winslet M: The IGF system in carcinogenesis and its implication for cancer therapy. Curr Oncol 18: 301-302, 2011.

11. Samani AA, Yakar S, Le Roith D and Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20-47, 2007.

12. Héron-Milhavet L and LeRoith D: Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 277: 15600-15606, 2002.

13. He Y, Zhang J, Zheng J, Du W, Xiao H, Liu W, Li X, Chen X, Yang L and Huang S: The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells. Oncol Res 19: 35-43, 2010.

14. Abe S, Funato T, Takahashi S, Yokoyama H, Yamamoto J, Tomiya Y, Yamada-Fujimura M, Ishizawa K, Kameoka J, Kaku M, Harigae H and Sasaki T: Increased expression of insulin-like growth factor-I is associated with Ara-C resistance in primary acute myeloid leukemia. Tohoku J Exp Med 209: 217-228, 2006.

15. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Baier TG, Jenne EW, Blum W, Schönberg D and Hartmann KK: Influence of antibodies against IGF-I, insulin or their receptors on proliferation of human acute lymphoblastic leukemia cell lines. Leuk Res 16: 807-814, 1992.

16. Gilmore MJ, Prentice HG, Blacklock HA, Janossy G and Hoffbrand AV: A technique for rapid isolation of bone marrow mononuclear cells using Ficol-Metrizoate and the IBM 2991 blood cell processor. Br J Haematol 50: 619-626, 1982.

17. Schwarze CP, Neu S, Beck J, Mavridou K, Ranke MB and Binder G: Influence of IGF-I and cell density on MDRI expression in the T-lymphoblastoid cell line CCRF-CEM. Horm Res 52: 192-199, 1999.

18. Shimon I and Shpiberg O: The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 19: 233-240, 1995.

19. Doepfner KT, Spretini O and Arcaro A: Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 21: 1921-1930, 2007.

20. Baier TG, Jenne EW, Blum W, Schönberg D and Hartmann KK: Influence of antibodies against IGF-I, insulin or their receptors on proliferation of human acute lymphoblastic leukemia cell lines. Leuk Res 16: 807-814, 1992.

21. Gilmore MJ, Prentice HG, Blacklock HA, Janossy G and Hoffbrand AV: A technique for rapid isolation of bone marrow mononuclear cells using Ficol-Metrizoate and the IBM 2991 blood cell processor. Br J Haematol 50: 619-626, 1982.

22. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O and Axelson M: Cyclolignans as inhibitors of the insulin-like growth factor-I receptor and malignant cell growth. Cancer Res 64: 226-232, 2004.

23. Qiang YW, Kopantzev E and Rudikoff S: Insulin like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99: 4138-4146, 2002.

24. Rodon J, DeSantos V, Ferry RJ Jr and Kurzrock R: Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7: 2575-2588, 2008.

25. Gregory CW, DeGeorges A and Sikes RA: The IGF axis in the development and progression of prostate cancer. Recent Res Dev Cancer 3: 437-462, 2001.

26. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 65: 311-320, 1992.

27. Burren CP, Berka JL, Edmondson SR, Wether GA and Batch JA: Localization of mRNAs for insulin-like growth factor-I (IGF-I), IGF-I receptor, and IGF binding proteins in rat eye. Invest Ophthalmol Vis Sci 37: 1459-1468, 1996.

28. Clemons DR and Maile LA: Integral membrane proteins that function coordinately with the insulin-like growth factor-I receptor to regulate intracellular signaling. Endocrinology 144: 1664-1670, 2003.

29. Turner HE, Harris AL, Melmed S and Wass JA: Angiogenesis in endocrine tumors. Endocr Rev 24: 600-632, 2003.

30. Wu KD, Zhou L, Burtrum D, Ludwig DL and Moore MA: Antibody targeting of the insulin like growth factor-I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56: 343-357, 2007.

31. Karamouris MV and Papavassiliou AG: Targeting insulin-like growth factor-I in breast cancer therapeutics. Crit Rev Oncol Hematol 84: 8-17, 2012.

32. Hopkins A, Crowe PJ and Yang JL: Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol 136: 639-650, 2010.